Question 1

What is follistatin?

Accepted Answer

Follistatin is a protein the body makes for itself, and its job is to switch other signals off. A 1998 review describes it as a secreted protein is able to bind and neutralise the actions of many members of the Transforming Growth Factor-beta family of proteins. That family includes myostatin, which is the signal that puts a ceiling on muscle growth. A 2016 study states the muscle link in one line, calling follistatin a liver-derived inhibitor of the muscle-growth inhibitor myostatin, and blocking a brake is the whole reason this name is searched for. What a reader needs next is the form that was studied, because almost none of the muscle work used a protein anyone could buy in a vial.

Question 2

What form of follistatin was actually studied?

Accepted Answer

Three forms appear in the record, and only one of them is a protein given by injection. The first is gene therapy. A 2024 delivery paper reports that systemic administration of follistatin DNA gene therapy with FAST-PLVs raised circulating follistatin levels, in work run in mouse and non-human primate models, where the animal's own cells are made to produce the protein. The second is messenger RNA wrapped in fat, and a 2024 cancer study used follistatin mRNA lipid nanoparticles to lower activin A in mice. The third is the protein itself, delivered to rats through an implanted pump in one study, while one human study used a virus to carry a follistatin gene into muscle. A gene therapy in a mouse and a vial of peptide are different things. Nearly all of the muscle evidence belongs to the first category.

Question 3

What is follistatin 344?

Accepted Answer

FS344 is one natural version of the follistatin gene, and the number is a length rather than a brand. It reached people once, and not as an injection of peptide. A 2018 review of exercise in muscle disease describes a study that evaluates the effects of intra-muscular injections of an isoform of follistatin (FS344) by AAV1 in combination with exercise in a small group of patients with inclusion body myositis. AAV1 is a harmless virus used to carry a gene into cells, so what was injected was genetic instructions. The reported outcome is modest. An improvement in physical capacity was associated to higher exercise levels in those patients. A different number, FS-288, names the protein isoform used in the rat work below, so the two numbers are not interchangeable.

Question 4

What happened when the protein itself was given?

Accepted Answer

One study answers that, in rats, and the result is not what the search interest expects. The authors set the question up plainly. Local administration of recombinant FST protein, if effective, would be more clinically translatable but has yet to be investigated following muscle reinnervation. So they ran it. In total, 72 Sprague-Dawley rats underwent temporary denervation or sham denervation, and after reinnervation, rats received FST protein (isoform FS-288) or sham treatment via a subcutaneous osmotic pump delivery system. The muscle outcomes went the wrong way. In those rats, follistatin treatment resulted in smaller muscles after 3 months denervation, and reduced force after 3 months sham denervation. One outcome went the other way, since direct FST protein delivery enhanced satellite cell counts following reinnervation in the same animals. The authors' own summary is that follistatin had mixed effects on muscle weight and force.

Question 5

Does follistatin build muscle?

Accepted Answer

In animals given a gene for it, muscle grew. In the one study that injected the protein, it did not. Begin with the strongest animal result. A 2024 paper reports that follistatin DNA gene therapy significantly increased muscle mass and grip strength in the animal models it used. The genetics point the same way. A 1998 review reports that gene targetting has shown that follistatin is essential for normal development, and that in its absence, mice die soon after birth with a range of defects including insufficient muscle development. A 2022 transgenic mouse study found the opposite case, where deletion of the FAP-specific follistatin gene results in impaired muscle stem cell function, enhanced fibrosis, and delayed muscle regeneration. All of that is about how much follistatin an animal's own tissue makes, and none of it measures a person injecting a vial.

Question 6

Does follistatin burn fat?

Accepted Answer

No study among the research behind this page measured fat loss in a person given follistatin. What exists points two ways at once. In the dish it releases fat. A 2021 study reports that in human adipocytes, follistatin dose-dependently increases free fatty acid release. Adipocytes are fat cells, and releasing fatty acids is not the same as losing fat, which needs something to burn it. The same paper found the association runs the unwelcome way. Elevated circulating follistatin associates with an increased risk of T2D by inducing adipose tissue insulin resistance in those human cohorts. Animal cancer work shows fat being preserved rather than lost. A 2024 mouse study reports that its therapy preserved the cross-sectional area of muscle fibers and adipose tissues. Preventing wasting in a sick mouse and stripping fat from a healthy adult are different questions, and the second has not been asked.

Question 7

Why does follistatin keep showing up in exercise studies?

Accepted Answer

Because in those trials it is something measured, not something given. That distinction carries most of the confusion around this name. A 2025 trial randomised sixty overweight and obese men to four groups of resistance training. Combined training elicits the greatest increases in follistatin, follistatin/myostatin ratio, and adiponectin in those men. A 2024 trial in twenty-one older individuals with sarcopenia found that both exercise programmes improved FST among other blood markers. A 2025 vibration trial saw the same pattern in its blood panel, and a 2024 creatine trial in forty participants reported a significant increase in the ratio of follistatin/myostatin. Read what those four trials did. Nobody was given follistatin in any of them, and training moving a blood level is evidence about exercise rather than about an injection.

Question 8

Is follistatin the same as follistatin-like 1 or 3?

Accepted Answer

They are related proteins with different names, different genes and different bodies of work. A 2023 review sets out the family in two steps. Follistatin (FST) is a glycoprotein, which is a protein with sugar chains attached to it. The review adds that follistatin-like 3 (FSTL3) shares the same trick of mopping up growth signals. Sharing a trick is not being the same molecule. Follistatin-like 1 is a third protein again, and a 2026 mouse study says FSTL1 modulates energy metabolism in peripheral tissues and is also found in the brain. The split matters when reading a claim. A 2013 review notes that the role of Activin Type IIB soluble receptors and Follistatin-like 3 mimetics is less certain because of side effects. That line is about FSTL3 mimics, so quoting it as a follistatin result changes the subject.

Question 9

Has follistatin been given to people?

Accepted Answer

Once, as a gene carried by a virus, in a small group of patients. Everything else done in people measured follistatin already in the blood. The one administration study is the inclusion body myositis work, where intra-muscular injections of an isoform of follistatin (FS344) by AAV1 were combined with exercise. The observational human record is larger and answers a different question. A 2021 study followed 4060 people in Sweden for 19 years and linked higher follistatin to later diabetes. A 2016 study infused eight male cirrhosis patients and eight healthy control participants, and the peak follistatin change was significantly decreased in patients with liver cirrhosis. A registered trial measured serum follistatin in men with heart disease taking omega-3. Not one of those gave anybody follistatin, and a level in the blood and an injection are different things.

Question 10

What is known about follistatin side effects?

Accepted Answer

Very little is documented, because very little has been given to anybody. The clearest adverse signal is in the rat study, and it is an efficacy result rather than a toxicity one. Follistatin treatment resulted in smaller muscles after 3 months denervation in those rats, which is the opposite of the reason people look this compound up. A 2026 mouse cancer study reports its delivery system working without adverse effects, which is about lipid nanoparticles in mice rather than an injection in a person. The one caution written about this family is about a relative. A 2013 review notes that the role of Activin Type IIB soluble receptors and Follistatin-like 3 mimetics is less certain because of side effects. An absence of reported harm, in work that never dosed a person, is not a finding about harm.

Question 11

What amounts appear in the literature?

Accepted Answer

None that a reader could apply, and the reason is the delivery rather than secrecy. In the rat study the protein went in continuously. Rats received FST protein (isoform FS-288) or sham treatment via a subcutaneous osmotic pump delivery system, which is a small implant that seeps its contents over days. There is no injection schedule to report, because there were no injections. In the human study the unit was not an amount of protein at all. It was intra-muscular injections of an isoform of follistatin (FS344) by AAV1, and the quantity that matters there is viral particles rather than milligrams. The mouse cancer work used follistatin mRNA lipid nanoparticles, which is a third unit again. Three studies, three delivery systems, and nothing in that set converts into an amount for a vial.

Question 12

How expensive is follistatin?

Accepted Answer

No price appears among the sources behind this page, and the forms those sources describe are not things with a shelf price. One team produced recombinant protein and implanted it in rats with an osmotic pump, another used a virus to deliver a gene into human muscle in a hospital study, and a third built a proteolipid vehicle, which is an engineered particle, to carry DNA through the bloodstream of mice and monkeys. Those are manufacturing routes for a laboratory or a clinical programme rather than things with a per-milligram price. So the honest answer to a price question is that the research does not contain one, and the things it does describe are not the thing being priced.

Question 13

What is follistatin being developed for?

Accepted Answer

Cancer wasting, mostly, and as a genetic medicine rather than as a muscle compound. A 2024 study built follistatin mRNA lipid nanoparticles to lower activin A, a signal that drives both tumour spread and wasting. In a murine head and neck squamous cell carcinoma model this led to a reduction in tumor burden and suppression of metastatic spread. A 2026 study did something similar in lung tumours. Its particles loaded with follistatin-coded mRNA efficiently mitigated cancer cachexia by improving food intake, maintaining body weight, and preserving muscle and adipose tissues in those mice. Cachexia is the severe muscle and fat loss that advanced illness causes. Notice the direction of travel. The developers are not chasing extra muscle in a healthy body, but trying to stop losses in a sick one, which is a different target.

Question 14

Is follistatin an approved medicine?

Accepted Answer

It is not approved as a medicine among the sources behind this page, and the suggestion that it might be one is older than most readers expect. A 1998 review ends on the possibility rather than a result, saying it may be possible to use follistatin as a therapeutic agent in these disorders. That was the position nearly thirty years ago, and nothing in these sources records an approval since. What did reach clinical development is a set of antibodies with other names. A 2024 review lists novel compounds in the pipeline, such as Bimagrumab, Trevogrumab, and Garetosmab, which inhibit activin and myostatin signaling in trials. Read that substitution carefully: the pharmaceutical route to blocking myostatin went around follistatin rather than through it.

Question 15

Does follistatin protect muscle during weight loss?

Accepted Answer

It is part of the system that does, which is a claim about biology rather than about a vial. A 2024 review explains the set-up. The myostatin-activin-follistatin-inhibin system appears to be crucial for muscle and bone maintenance during weight loss in the patients it discusses. Activins and myostatin promote muscle degradation, while follistatins inhibit their activity in states of negative energy balance, thereby preserving lean mass. That describes what the body already does when food is short, rather than reporting anyone being given follistatin while dieting. A related protein does have a weight result, and it is worth keeping separate. A 2026 study found that intranasal FSTL1 delivery promoted weight loss and improved insulin sensitivity in obese mice. FSTL1 is not follistatin, and nasal delivery in a mouse is not a result about either.

Question 16

How settled is the follistatin research?

Accepted Answer

Less settled than the number of papers suggests, and the reviews say so themselves. A 2023 review of follistatin in metabolic disease is blunt about it. The exact function of them has still not been established, it writes, and the outcomes are contradictory and do not allow to draw exact conclusions. That is a review of the human blood-marker literature, which is the largest body of work carrying this name. Its verdict is that the direction of the association is still in dispute. The classification is unsettled too. A 2022 review files Follistatin-like1 among pro-inflammatory adipokines, which are signalling proteins released by fat tissue. A molecule one field reads as protective and another reads as inflammatory is still being argued over.

Question 17

How is follistatin thought to work?

Accepted Answer

By binding signals before they reach their receptors, so the brake never gets applied. A 1998 review gives the general form. Follistatin binds and neutralises the actions of many members of the Transforming Growth Factor-beta family, myostatin among them. A 2026 review of testosterone shows the same mechanism from the other end. Testosterone signalling upregulates follistatin that blocks signaling through the TGF-beta pathway to promote myogenesis and inhibit adipogenesis in muscle tissue. Myogenesis is the making of new muscle fibres. A 2022 mouse study adds a living tissue, where activated FAPs secrete follistatin, a promyogenic factor, thereby boosting the recovery process after injury. All three describe follistatin made inside the body, at the place it acts. Whether the same follows when it arrives from outside is what the rat pump study tried to answer, and that answer was mixed.

Follistatin